national disclosure summit on Pharmaceutical and Medical Device Disclosure, Transparency and Aggregate Spend Conference



Overview | Agenda/Faculty Materials | Training Program | Promotional Opportunities
Administration | Speaking Proposals | Past Events | Contact Us | Home




THE SECOND NATIONAL DISCLOSURE SUMMIT CONTENT IS NOW AVAILABLE IN VARIOUS POST CONFERENCE FORMATS

The Second National Disclosure Summit conference content is now available in a variety of formats.

You may purchase the Colloquium streaming content in the following formats: Data DVD, iPod™ Touch, Flash Drive or online archive (6 months). You may also purchase individual presentations in an online archive (6 months) format.

YOU CAN PURCHASE JUST THE SECOND NATIONAL DISCLOSURE SUMMIT CONTENT AS FOLLOWS:

iPod Touch of 2010 Second National Disclosure Summit Presentations today!
$429
Order Now

Flash Drive of 2010 Second National Disclosure Summit Presentations today!
$595
Order Now

Online Archive of 2010 Second National Disclosure Summit Presentations today!
Complete conference: $595
Order Now

FINALLY YOU MAY PURCHASE SECOND NATIONAL DISCLOSURE SUMMIT INDIVIDUAL PRESENTATIONS:
Click here to purchase individual presentations for $59.95 in online archive format (6 months of access - 24/7).





national pharmaceutical and medical device disclosure and transparency conference

SECOND ANNUAL SUMMIT ON DISCLOSURE, TRANSPARENCY AND AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES
March 3 - 5, 2010

Onsite:
Renaissance Washington DC Hotel

Online:
Live and Archived for 6 Months


SUMMIT GRANTORS

SILVER GRANTOR





BRONZE GRANTORS

















DISCLOSURE SUMMIT IS A


THE CONFERENCE HOTEL IS SOLD OUT!
The conference hotel, the Renaissance Washington DC Hotel, is sold out. Alternate hotels are available.
Click here for info.

DISCLOSURE SUMMIT TRAINING PROGRAM



KEYNOTE SPEAKER

Mary E. Riordan, Esq.
Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, Washington, DC

DISCLOSURE SUMMIT TOPICS

PRECONFERENCE: DISCLOSURE BOOT CAMP

  • Understanding the Forces Driving Disclosure: State Legislators, MedPAC, US Congress: The Sunshine Act, State Enforcers, OIG, Settlements and CIAs
  • Introduction to Existing State Disclosure Laws and Regulations: Massachusetts, Minnesota, Nevada, Vermont, Washington, DC and West Virginia
  • Aggregate Spend 101: The Nuts and Bolts of an Aggregate Spend Program

    THE SUMMIT

  • How Disclosure and Transparency are Reshaping Pharmaceutical and Device Marketing and Compliance
  • Update on the Physician Payments Sunshine Act
  • Pushing the Envelope: What's Next for the States?
  • The Evolving Role of the OIG
  • How Disclosure Will Reshape State and Federal Enforcement Initiatives
  • Early Lessons from Lilly and Merck's Initial Public Disclosures
  • The Physician-Industry Relationship: Flaws and Solutions
  • How to Manage New Clinical Trial Disclosure Requirements
  • Capturing the Right Information and Ensuring Its Integrity
  • Benchmarking Data: Comparing Your Practices to Those of Your Peers
  • Industry Disclosure Best Practice Roundtable

  • THE DISCLOSURE SUMMIT IS DEDICATED TO THE MEMORY OF MIKE BIGELOW (1967 - 2009)

    Former Assistant General Counsel at Eli Lilly




    SECOND ANNUAL SUMMIT ON DISCLOSURE, TRANSPARENCY AND
    AGGREGATE SPEND FOR DRUG, DEVICE AND BIOTECH COMPANIES

    A Pharma Congress Conference
    March 3 - 5, 2010

    ONSITE
    Renaissance Washington DC Hotel
    Washington, DC


    OR
    ONLINE
    In your own office or home live via the Internet
    with 24/7 access for six months


    CO CHAIRS


    Jonathon L. Kellerman
    Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Florham Park, NJ

    Daniel A. Kracov, Esq.
    Partner, Arnold & Porter, Washington, DC

    Paul J. Silver
    Managing Director, Huron Consulting Group, LLC, Atlanta, GA

    Jack T. Tanselle
    Director, Navigant Consulting, Inc., Chicago, IL

    Michael Varlotta
    Senior Director, Department of Medical Education, Medical Affairs, Centocor, a wholly owned subsidiary of Johnson & Johnson, Horsham, PA
    FEDERAL AND STATE POLICY MAKERS

    Christopher J. Armstrong, Esq.
    Investigative Counsel, Committee on Finance, US Senate, Staff, Senator Charles Grassley, Ranking Member, Washington, DC

    Stephen Cha, MD, MHS
    Professional Staff Member, Energy and Commerce Committee, US House of Representatives, Washington, DC

    George Till, MD
    State Legislator, Vermont, Underhill, VT
    FEDERAL AND STATE PROSECUTORS AND REGULATORS

    Melissa J. Lopes, Esq.
    Deputy General Counsel, Massachusetts Department of Public Health, Boston, MA

    Mary E. Riordan, Esq.
    Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, Washington, DC

    James G. Sheehan, Esq.
    New York State Medicaid, Inspector General, Former Associate United States Attorney, US Attorney's Office, Eastern District of Pennsylvania, Albany, NY


    Gerald Sullivan, Esq.
    Assistant United States Attorney, US Attorney's Office, Eastern District of Pennsylvania, Philadelphia, PA
    POLICY EXPERTS

    Guy M. Chisolm, III, PhD
    Director, Innovation Management and Conflict of Interest Program, Vice Chairman, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

    Bernard Lo, MD
    Professor of Medicine and Director Program in Medical Ethics, Department of Medicine, University of California, San Francisco, Chair, Committee on Conflict of Interest in Medical Research, Education, and Practice; Institute of Medicine, San Francisco, CA

    Frank W. LoGerfo, MD
    William V. McDermott Distinguished Professor of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    James Roosevelt, Jr., Esq.
    President and Chief Executive Officer, Tufts Health Plan, Former Associate Commissioner for Retirement Policy, US Social Security Administration, Boston, MA

    Thomas P. Stossel, MD
    Director, Translational Medicine Division, Senior Physician, Hematology Division, American Cancer Society, Professor of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
    COMPLIANCE PROFESSIONALS AND INHOUSE COUNSEL

    Diane Cruz-Burke, Esq.
    Assistant General Counsel, Eli Lilly and Company, Indianapolis, IN




    Jacqueline K. Huber
    Corporate Vice President and Chief Compliance Officer, Biomet, Inc., Warsaw, IN

    Beth Margerison
    Associate Director, Ethics and Compliance, Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Rore Middleton
    Corporate Compliance Consultant, Purdue Pharma, Stamford, CT

    Brian S. McGowan, PhD, CCMEP
    Senior Director, Independent Medical Education, Pfizer, Collegeville, PA



    Jeffrey S. Paden
    Compliance Director, GlaxoSmithKline, Research Triangle Park, NC


    Heather Reilly Powell, Esq.
    Director, Compliance Training and Reporting, Daiichi Sankyo, Inc., Former Associate Director, Global Compliance, Cephalon, Inc., Parsippany, NJ

    Trudy J. Seeley, Esq.
    Compliance Manager, State Law Compliance, and US Corporate Compliance, sanofi-aventis, Bridgewater, NJ




    Betsy Van Hecke
    Vice President Ethics and Compliance, MedTronic Spinal and Biologics, Minneapolis, MN




    Patrick Witmer
    Director, Global Public Policy and Corporate Responsibility, Merck & Co., Inc., Whitehouse Station, NJ
    A PANEL OF COMPLIANCE TECHNOLOGY EXPERTS

    Michael Bell, Esq.
    President, R-Squared, Princeton Junction, NJ

    Mitch Chi
    Senior Vice President Sales, Health Market Science, King of Prussia, PA




    Kim Life, Esq.
    Principal, Life Compliance Solutions, Former Associate Director, Business Conduct, Gilead Sciences, San Francisco, CA (Moderator)

    John Patrick Oroho, Esq.
    Executive Vice President, Porzio Pharmaceutical Services, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ

    Don Soong
    Senior Director, Compliance Solutions Development, Cegedim Dendrite, Bedminster, NJ
    ADVISORS AND LEGAL COUNSEL

    Eric M. Baim, Esq.
    Associate, Hogan & Hartson, Washington, DC

    John T. Bentivoglio, Esq.
    Partner, Skadden Arps LLP, Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, Washington, DC

    Brian A. Bohnenkamp, Esq.
    Associate, King & Spalding LLP, Counsel, Ad Hoc State Law Compliance Group, Washington, DC

    Jennifer Colapietro
    Director, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers, Florham Park, NJ

    Daniel F. Donovan, III, Esq.
    Partner, Government Advocacy & Public Policy Practice Group , King & Spalding, Former Senior Investigative Counsel to Senator Charles E. Grassley (R-IA), Committee on Finance, US Senate, Washington, DC

    Michael N. Druckman, Esq.
    Partner, Hogan & Hartson, Washington, DC

    Sarah K. Giesting, Esq.
    Associate, Epstein Becker & Green, New York, NY

    Jeffrey L. Handwerker, Esq.
    Partner, Arnold & Porter, Washington, DC

    Marci Juneau
    Manager, Life Sciences Advisory Services, Huron Consulting Group, Atlanta, GA

    William A. Sarraille, Esq.
    Partner, Sidley Austin Brown & Wood, Washington, DC

    William M. Mandell, Esq.
    Partner, Pierce & Mandell, PC, Boston, MA

    Thomas Sullivan
    President and Founder, Rockpointe Corporation, Columbia, MD

    Manny Tzavlakis
    Director, Life Sciences Advisory Services, Huron Consulting Group, New York, NY

    Jon Wilkenfeld, MBA
    President, Potomac River Partners, Vienna, VA

    THE DISCLOSURE SUMMIT CONTENT IS NOW AVAILABLE IN VARIOUS POST CONFERENCE FORMATS

    You may now purchase the packaged Disclosure Summit Training Program, which includes preconference readings and online courses, the conference video with synchronized PowerPoint presentations and the post conference online exam. This content is perfect for corporate compliance training programs and can be purchased at deep group discounts. Click here for more info.

    Alternatively, you may purchase just the Summit streaming content in the following formats: Data DVD, iPod™ nano, Flash Drive or online archive (6 months). You may also purchase individual presentations in an online archive (6 months) format. Click here for more info.


    THE TIME IS NOW FOR NEW, EFFICIENT AND COST EFFECTIVE ALTERNATIVES TO TRADITIONAL LEARNING APPROACHES

    A variety of forces - the nation's economic crisis, costly and difficult air travel, the mandate for cost efficiency in healthcare, the proliferation of greater Internet bandwidth, the emergence of the popularity of online video via You Tube, and the explosion of online training in the health sector - has come together to create both a dramatic need and an extraordinary opportunity for innovative approaches to sharing new ideas and best practices. This Summit offers not only traditional conference attendance, but also to opportunity to attend the event live and archived online.

    How can we be expected to reform the nation's health system if we can not reform the way we do our own business?


    CONTENT OPTIONS
    TRADITIONAL CONFERENCE REGISTRATION
    Register for Preconference Disclosure Summit Boot Camp and/or Conference.

    DISCLOSURE TRAINING PROGRAM
    The Disclosure Summit is offering a Disclosure Training Program in the form of an optional course within the conference for attendees wishing to take a deeper dive into the Summit's subject matter. The Program requirements are:
    • Completion of preconference readings - Click here to review pre-course reading
    • Completion of five online course modules on Disclosure prepared by Arnold & Porter and Huron Consulting - Click here to review
    • Consideration of a series of preconference questions - Click here to review preconference questions
    • Attend Preconference Disclosure Summit Boot Camp either in person or online
    • Attend Summit either in person or online
    • Successful completion of a post-conference online examination - Click here to take sample examination.

    Attendees who successfully complete Program requirements will receive a certificate of completion.


    PARTICIPATION OPTIONS
    TRADITIONAL ONSITE ATTENDANCE
    Simply register, travel to the conference city and attend in person.

    Pros: subject matter immersion; professional networking opportunities; facility interaction

    LIVE AND ARCHIVED INTERNET ATTENDANCE
    Watch the conference in live streaming video over the Internet and at your convenience at any time 24/7 for the six months following the event.

    The archived conference includes speaker videos and coordinated PowerPoint presentations.

    Pros: Live digital feed and 24/7 Internet access for next six months; Accessible in office, at home or anywhere worldwide with Internet access; Avoid travel expense and hassle; No time away from the office







    INTERNET INTERFACE SAMPLE

    Click here for a sample stream
    THE GROUP REGISTRATION/ONLINE TRAINING ALTERNATIVE
    By arranging to license online group access to the Summit Disclosure Summit Training Program, pharmaceutical, device and biotech companies subject to disclosure and aggregate spend requirements can implement company-wide online training programs. The company training coordinator can assign and track online participation. Successful completion of the training can be evidenced by passing the post conference training examination.

    HERE IS AN EXAMPLE OF A PHARMA COMPANY DISCLOSURE TRAINING PROGRAM
    SAVE THE DATE
    FOURTH INTERNATIONAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS
    Sponsored by Pharmaceutical Compliance Forum
    May 17 - 19, 2010
    Berlin, Germany
    www.InternationalPharmaCongress.com
    FIFTH FDA REGULATORY SYMPOSIUM
    A Hybrid Conference and Internet Event
    Addressing FDA's Regulatory Agenda for 2010 and Beyond
    Media Partners: Harvard Health Policy Review and RxCompliance Report
    October 2010
    Washington, DC
    www.FDASymposium.com
    ELEVENTH PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS
    Transformational Learning - Effective Knowledge Exchange
    Sponsored by Pharmaceutical Compliance Forum
    Media Partners: Harvard Health Policy ReviewM
    November 2010
    Washington, DC
    www.PharmaCongress.com

    We subscribe to the HONcode principles of the HON Foundation. Click to verify.



    Overview | Agenda/Faculty Materials | Training Program | Promotional Opportunities
    Administration | Speaking Proposals | Past Events | Contact Us | Home




    © Health Care Conference Administrators
    Contact Webmaster